Cartesian Therapeutics (RNAC) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$16.9 million.
- Cartesian Therapeutics' Net Cash Flow fell 11282.71% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.8 million, marking a year-over-year decrease of 15416.69%. This contributed to the annual value of $136.0 million for FY2024, which is 55799.91% up from last year.
- As of Q3 2025, Cartesian Therapeutics' Net Cash Flow stood at -$16.9 million, which was down 11282.71% from -$20.1 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Net Cash Flow peaked at $132.0 million during Q3 2024, and registered a low of -$34.0 million during Q3 2023.
- Its 5-year average for Net Cash Flow is $267263.2, with a median of -$6.6 million in 2024.
- The largest annual percentage gain for Cartesian Therapeutics' Net Cash Flow in the last 5 years was 741687.12% (2022), contrasted with its biggest fall of 99278.35% (2022).
- Quarter analysis of 5 years shows Cartesian Therapeutics' Net Cash Flow stood at -$582000.0 in 2021, then plummeted by 992.78% to -$6.4 million in 2022, then soared by 57.42% to -$2.7 million in 2023, then plummeted by 142.73% to -$6.6 million in 2024, then plummeted by 157.57% to -$16.9 million in 2025.
- Its last three reported values are -$16.9 million in Q3 2025, -$20.1 million for Q2 2025, and -$32.2 million during Q1 2025.